Table 2. Univariate and multivariate analysis of clinical factors on 1,083 samples with OS.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |||
| Age (>60 vs. ≤60) | 1,082 | 2.020 (1.465–2.784) | <0.001 | 2.622 (1.709–4.023) | <0.001 | |
| Race (White vs. Asian and Black or African American) | 993 | 0.912 (0.615–1.350) | 0.644 | |||
| PAM50 (HER2, Basal and Lum B vs. Lum A) | 1,042 | 1.576 (1.136–2.186) | 0.006 | 1.495 (0.954–2.342) | 0.080 | |
| T stage (T4 and T3 vs. T1and T2) | 1,079 | 1.608 (1.110–2.329) | 0.012 | 1.703 (1.030–2.816) | 0.038 | |
| N stage (N3 vs. N0, N1, and N2) | 1,063 | 2.767 (1.610–4.756) | <0.001 | 2.886 (1.499–5.555) | 0.002 | |
| Radiation therapy (yes vs. no) | 986 | 0.576 (0.394–0.841) | 0.004 | 0.605 (0.402–0.911) | 0.016 | |
| TP53 (high vs. low) | 1,082 | 1.360 (0.986–1.875) | 0.061 | 1.002 (0.661–1.519) | 0.994 | |
| PIK3CA (high vs. low) | 1,082 | 1.258 (0.912–1.736) | 0.162 | |||
| MYC (high vs. low) | 1,082 | 0.853 (0.620–1.173) | 0.329 | |||
| SLC7A5(high vs. low) | 1,082 | 1.709 (1.234–2.367) | 0.001 | 1.925 (1.202–3.083) | 0.006 | |
OS, overall survival; TP53, tumor protein p53; PIK3CA, phosphatidylinositol 3-kinases.